Actively Recruiting

Age: 40Years +
All Genders
NCT07140367

"Transarterial Microembolization (TAME) in Inflammatory Knee Pathology"

Led by Istituto Ortopedico Rizzoli · Updated on 2026-04-07

43

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

Sponsors

I

Istituto Ortopedico Rizzoli

Lead Sponsor

O

Ospedale San Giuseppe Moscati, Avellino

Collaborating Sponsor

AI-Summary

What this Trial Is About

Patients with knee OA and chronic pain refractory to at least 3 months of conventional conservative therapy will be included in the study, which will evaluate the clinical results obtained after treatment with selective arterial embolization (selection and enrollment, treatment with selective arterial embolization, follow-up checks). Forty-three patients will be included in the study and will undergo the transarterial microembolization procedure after signing the informed consent form for participation in the study and the collection of anamnestic data. Subsequently, patients will be followed up with clinical evaluation at 1, 3, 6, 12, and 24 months of follow-up or until possible dropout for other treatment.

CONDITIONS

Official Title

"Transarterial Microembolization (TAME) in Inflammatory Knee Pathology"

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with degenerative knee disease
  • Age over 40 years
  • Moderate knee osteoarthritis (grade 2-3) with indication for total knee arthroplasty
  • Knee osteoarthritis with inflammatory symptoms such as night pain, pain at rest, swelling, or redness
  • Persistent moderate or severe knee pain with VAS score greater than 4
  • Failure of at least 3 months of conservative treatments including physical therapy, NSAIDs, injections, or orthobiologics
  • Signed informed consent form
  • Eligibility confirmed by internal multidisciplinary discussion on degenerative-inflammatory disease
Not Eligible

You will not qualify if you...

  • Mentally incompetent patients
  • Trauma to the knee within 6 months before treatment
  • Malignant tumors
  • Rheumatic diseases
  • Use of anticoagulant or anti-platelet therapy (even if discontinued 5 days prior)
  • Abuse of alcohol, drugs, or medications
  • Knee surgery within the previous 12 months
  • INR less than 2
  • Platelet count below 30,000
  • Renal failure with GFR below 30 ml/min
  • Pregnancy
  • Allergy to iodinated contrast agents
  • Unable to undergo MRI examination

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

IRCCS Istituto Ortopedico Rizzoli

Bologna, Bologna, Italy, 40136

Actively Recruiting

Loading map...

Research Team

G

Giancarlo Facchini, Medicine and Surgery

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here